88 results about "Thyroid Gland Hormone" patented technology

The present invention provides pharmaceutical formulation for thyroid hormones which allow safe and stable administration by mouth within the ambit of the narrow therapeutic index prescribed in the case of thyroid dysfunctions, as well as procedures for obtaining

The invention provides a method for efficiently inducing reprogramming of human body cells into pluripotent stem cells, belonging to the field of biomedicine. The method provided by the invention comprises the following step: before carrying out nuclear reprogramming on body cells, culturing the body cells for 2-4 days in a culture medium containing thyroid hormone T3. The method provided by the invention can increase the iPSC (induced pluripotent stem cell) induction efficiency by 20-100 times to about 1.2%, and shorten the induction cycle to 12-16 days; and meanwhile, different clones of the iPSC obtained by induction have uniform cellular morphology, multiplication capacity and pluripotent gene expression, and can be used for researching human diseases.

The invention provides a pyridazinone derivative and an application thereof, the pyridazinone derivative with the structure shown in the formula (I) provided by the invention has good activity as a thyroid hormone beta receptor agonist by selecting a specific modification group. The compound can be used for treating and / or preventing diseases caused by thyroid hormone regulation.

The present invention relates to sulfonic acid containing compounds of formula IB, in which G, R1, R3 and T are as defined in the claims, that bind to thyroid receptors in the liver. Activation of these receptors results in modulation of gene expression of genes regulated by thyroid hormones. The compounds can be used to treat diseases and disorders including metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome X and diabetes.

The invention discloses an improved Neurobasal B27 culture medium. One liter of a Neurobasal culture solution comprises 0.09-0.11 g of biotin, 18-22 micrograms of corticosterone, 1-3 g of L-carnitine, 0.9-1.1 g of linoleic acid, 0.9-1.1 g of ethanol amine, 0.9-1.1 g of linolenic acid, 13-17 g of D(+)-galactose, 6-7 micrograms of progesterone, 15-17 g of putrescine dihydrochloride, 0.08-0.12 g of retinyl acetate, 2.2-2.8 g of thyroid-hormone-removing bovine serum albumin, 0.8-1.5 g of DL-alpha-tocopherol, 2-3 g of catalase, 0.9-1.2 g of DL-alpha-tocopheryl acetate, 0.8-1.3 g of reduced glutathione, 42-52 micrograms of lipoic acid, 2-3 g of superoxide dismutase, 4-6 g of transferring, 3-5 g of human insulin and 0.12-0.16 mg of sodium selenite. The invention further discloses a preparing method and application of the improved Neurobasal B27 culture medium. The improved Neurobasal B27 culture medium can be used for researching the influence of thyroid hormones on the process that embryonic stem cells are differentiated into nerve cells.

The present invention relates to methods of treating or ameliorating certain neurodegenerative disorders (namely, dysmyelinating and demyelinating disorders) in patients in need of such treatment or amelioration. The invention provides methods of treating or ameliorating a patient in need of such treatment and includes the administration to the patient of: (a) thyroid hormones or thyroid hormone analogues; (b) cell replacement therapies involving the use of homogenous Oligodendrocyte Precursor Cells derived from embryonic stem cells that have been treated with thyroid hormones or thyroid hormone analogues; (c) gene therapy to correct mutated genes in vivo; or (d) a combination of two or more of (a), (b) and (c). The invention also provides compositions and formulations of thyroid hormones and thyroid hormone analogues for use in treating or ameliorating such disorders.

The invention provides molecular methods of screening chickens to determine those more likely to have a lean or fat phenotype by identifying the presence of at least one polymorphism in genetic material of a chicken in the thyroid hormone repressible gene (THRG) or its 3′ untranslated region (SEQ ID NO: 1) that is associated with a fat phenotype or a lean phenotype. The invention also provides methods of screening chickens to identify a polymorphism associated with a fat or lean phenotype. The invention further provides oligonucleotide probes and primers useful for detecting the polymorphisms associated with a fat or lean phenotype.

This invention discloses using SPR technology to simultaneously and quantitatively measure the concentrations of thyroid hormones and related antibodies in a serum sample, which can be used to evaluate thyroid functions and to diagnose thyroid diseases. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of relevant antibodies and antigens used for the detection of respective thyroid hormones and related antibodies in a serum sample.

The invention relates to the induction of the neuronal fate in neural stem cells or neural progenitor cells. The inventors have found that a neuronal fate in a neural stem cell or neural progenitor cell can be induced by expressing Nurr1 above basal levels within the cell. Nurr1 is a transcription factor of the thyroid hormone / retinoic acid nuclear receptor superfamily. It is shown herein that the expression of Nurr1 above basal levels in neural stem cells or neural progenitor cells increases the proportion of the cells which differentiate toward a neural fate. It has been found that in particular, dopaminergic neural stem cells or progenitor cells by a process including expression of Nurr1 above basal levels in the cells and contact of the cells with one or more factors supplied by or derived from Type I astrocytes of the ventral mesencephalon.

The invention provides a two-hybrid yeast cell for detecting thyrotropic hormone-like / antithyrotropic hormone compounds in a sample and a preparation method thereof, wherein a yeast contains pGBT9-TR yeast expression plasmids and pGAD424-GRIP1 yeast expression plasmids, wherein the pGBT9-TR yeast expression plasmids contain thyroid hormone receptor genes, and the pGAD424-GRIP1 yeast expression plasmids contain thyroid hormone receptor coactivated factor genetic fragments with the sequence of SEQ ID No.2. The invention also provides a bioassay method for detecting the thyrotropic hormone-like / antithyrotropic hormone compounds in the sample. The yeast and the bioassay method greatly improve the sensitivity of the thyrotropic hormone-like / antithyrotropic hormone compounds. The constructed yeast has stable characteristics and is easy to culture and screen; the screening process of the whole thyrotropic hormone-like / antithyrotropic hormone effect is simple to operate; and the required quantity of the sample is small, and the cost is low.

The invention provides a TSH (thyroid stimulating hormone) quantitative detection kit based on time-resolved fluoroimmunoassay, applicable to clinical screening of neonatal hypothyroidism. The preparation method of the kit is characterized by comprising the following steps of: 1, separating an antibody conjugate (Eu-Anti-TSH) from free rare earth ions (Eu<3+>) by using a specific chromatograph column; (2) using a bifunctional chelator (DTTA) for marking, wherein one end of the bifunctional chelator is chelated with rare earth ions (Eu) and the other end of the bifunctional chelator is connected with -NH2 of protein; adding beta-NTA to reinforcing liquid and regulating the concentration so that the fluorescence intensity of a finally obtained reagent is improved; and (4) adding a substitute Proclin300 for sodium azide to an analysis buffer system. Based on the characteristics of the steps in the preparation method, the TSH quantitative detection kit based on time-resolved fluoroimmunoassay can be produced and other in vitro diagnosis detection reagents can be developed.

The invention relates to highly stable alcohol-free, water-glycerol solutions of T4 thyroid hormone, with a reduced amount of T3 impurity, packaged via specific container arrangements. The containers are multi-barrier ones, in which a number of layers of specific materials separate the solution from contact with the external environment.

The present invention relates to pharmaceutical compositions comprising a thyroid hormone drug. The invention also relates to processes for the preparation of such compositions.

The invention relates to a thyroid hormone immunochromatographic test strip and a preparation method thereof, and a thyroid hormone immunochromatographic kit. The test strip comprises a substrate, anda sample pad, a marking pad, a detection film and an absorption pad which are arranged on the substrate, wherein the sample pad, the marking pad, the detection film and the absorption pad are sequentially connected from one end to the other end of the substrate; and the marking pad comprises a marking area, the marking area contains an animal thyroid hormone monoclonal antibody marked by fluorescent microspheres and a first complex marked by the fluorescent microspheres; the detection film is provided with a detection area and a quality control area, the detection area is coated with an animal thyroid hormone antigen, the quality control area is coated with a second complex, and the first complex and the second complex can be specifically combined. According to the thyroid hormone immunochromatographic test strip, fluorescence signals are detected by means of an immunoassay analyzer, the detection sensitivity is greatly improved by a photoelectromagnetic signal amplification system, interference of background colors is effectively eliminated, misjudgment of human factors on results is reduced, and the thyroid hormone immunochromatography test strip is safe, simple and rapid to operate and high in sensitivity.

The invention belongs to the field of biomedicines, particularly relates to the field of targeting drugs and more specifically relates to a liver-targeting compound with thyroid hormone receptor stimulating agent characteristics and a pharmaceutical composition of the liver targeting compound. The compound is a compound represented by a formula (1). The compound can be used for treating and / or preventing diseases induced by thyroid hormone regulation disorder and can also be used for effectively reducing lipids in blood plasma and liver cells.

The invention provides a traditional Chinese medicine composition for treating a thyroid nodule and a preparation method. The traditional Chinese medicine composition comprises the preparation raw materials: radix bupleuri, fructus aurantii, rhizoma cyperi, radix ranunculi ternati, ossa draconis, oyster shells, Chuanxiong rhizomes, radix paeoniae rubra, dried tangerine peels, rhizoma pinelliae and radix glycyrrhizae. The traditional Chinese medicine composition is used for treating preliminary-stage thyroid nodule by taking clinical symptoms, nodule size, hormone level and constitution regulation as multiple targets and taking the idea of promoting Qi circulation and dispelling melancholy and regulating Qi and resolving phlegm. The traditional Chinese medicine composition provided by the application can be used for effectively improving the clinical symptoms of a thyroid nodule sufferer, regulating and controlling the level of thyroid hormones, controlling and delaying the disease development of the thyroid nodule, improving the size of the nodule, regulating the global function of the sufferer and changing problems of constitutions prone to the thyroid nodule, thereby performing intervention fundamentally. Furthermore, drug dependence and thyroid function changes caused by long-term oral administration of hormone drugs and risks such as lifetime thyroid hormone drug dependence and nodule recurrence caused after thyroid nodule excision can be avoided to a relatively large extent.

Anguilliformes breeding water contains a thyroid hormone such as thyroxine, and a method for rearing anguilliformes includes a step for administering a thyroid hormone such as thyroxine, wherein the amount of the thyroid hormone to be administered changes as the anguilliforme fingerling changes from a transformation start phase (stage 1) to a transformation final phase (stage 2), and the amount of the thyroid hormone to be administered in the transformation final phase (stage 2) is less than the amount of the thyroid hormone to be administered in the transformation start phase (stage 1).

The present invention relates to a pharmaceutical container for the quantitative release of a single dose of T3 and T4 thyroid hormone solutions for oral administration, characterized in that the container is made of plastic with a Young's modulus of 10 to 80 MPa material.

The present patent relates to a method for qualitative identification and quantitative prediction of thyroid hormone disrupting chemicals base on the interaction between thyroid hormone receptor and co-regulators (coactivator and corepressor).The method identifies chemicals as passive antagonists, active antagonists and agonists by means of co-regulator involved molecular dynamics simulations, and predicts the relative disrupting potencies by use of binding free energy, therefore, may be used for screening of thyroid hormone disruptors among environmental pollutants. Upon more comprehensive consideration of the functioning mechanism of thyroid hormone receptor, the present invention is able to sufficiently identify thyroid hormone disruptors as agonists and antagonists, and gives more accurate prediction of the disrupting potency. Further, since nuclear receptors, just as thyroid hormone receptor, are strongly associated with co-regulators, the method may be expanded to the screening of nuclear receptor mediated endocrine disruptors.

The present invention provides a method for quickly detecting thyroid interferent. It uses the tail of xanopus tadpole of 53-55 stage as test material, and uses thyroid hormone to induce it to be absorbed and shortened, at the same time it makes the testing method undergo the process of exposure treatment, and utilizes the comparison of difference of shortened condition of tail of testing material exposure group and contrast to evaluate the thyroid interference activity.

Disclosed herein are pharmaceutical compositions to treat or prevent obesity, excess or overweight conditions, and metabolic syndrome comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones and / or an effective amount of one or more cholesterol-lowering agents. Further disclosed herein are methods of treating or preventing obesity, excess or overweight conditions, and metabolic syndrome comprising administering an effective amount of a pharmaceutical composition comprising one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones and / or an effective amount of one or more cholesterol-lowering agents.

The invention provides an application of thyroid hormone and an analogue thereof in preparation of a drug for treating alpha-thalassemia. The thyroid hormone and the analogue can be specifically applied in regulation of expression of zeta-globin genes, in the differentiation process of K562 cells, the thyroid hormone analogue can be specifically and significantly up-regulate the expression of thezeta-globin gene (HBZ) by up to 50 times, and in model animal zebrafish embryos, after treatment is performed by using the thyroid hormone and the analogue, the expression of the zeta-globin gene (hbae5) can also be specifically up-regulated by up to 30-70 times; therefore, the thyroid hormone and the analogue thereof can be used to specifically activate the expression of the zeta-globin genes, that is, to reactivate the silent zeta-globin genes in patients with the alpha-thalassemia to inhibit destruction of red blood cells, the thyroid hormone and the analogue realizes a method for preparingthe drug for treating the alpha-thalassemia, the economical, safe and effective method is provided for treatment of the alpha-thalassemia, and the method can be widely promoted and used.

Disclosed herein are pharmaceutical compositions to treat, prevent, reduce the incidence of, or reduce the severity of hepatic steatosis comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones. Further disclosed herein are methods of treating, preventing, reducing the incidence of, or reducing the severity of hepatic steatosis comprising administering an effective amount of a pharmaceutical composition of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones.

The invention discloses the application of MIT and / or DIT as a thyroid cancer marker and a kit. MIT and DIT are synthetic precursor substances of thyroid hormone T4, and the synthetic precursor substances have stable expression and constant existence in thyroid tissue and have high specificity and effectiveness. According to the invention, conditions that expression quantities of the MIT and the DIT are remarkably different in thyroid cancer tissue and thyroid normal tissue and the expression quantities of the MIT and the DIT in the thyroid cancer tissue are 100-200 times lower than the expression quantities of the MIT and the DIT in the normal tissue are found for the first time. Based on this, the MIT and DIT can be used as biomarkers for thyroid cancer detection, corresponding analysismethods can be used for preparing a thyroid cancer detection kit, and a novel technical means is provided for thyroid cancer detection, diagnosis, treatment and prognosis evaluation. According to theinvention, a thyroid cancer sample collected by a puncture needle can be accurately analyzed, and the purpose of ultra-efficient and high-sensitivity detection of the kit is achieved.

The use of a monocarboxylate transporter protein or a functional part, derivative and / or analogue thereof for altering transport of a thyroid hormone or a functional part, derivative and / or analogue thereof across a membrane. The monocarboxylate transporter protein preferably comprises MCT-8. An isolated molecule capable of specifically binding at least part of an MCT protein, at least part of a ligand of an MCT protein, or a nucleic acid encoding the MCT and / or ligand, is also herewith provided. Regulation of the bioavailability of thyroid hormone in a tissue enables interfering with diseases. The invention also provides pharmaceutical compositions comprising a compound capable of binding the MCT protein or capable of influencing the binding or transporting of a ligand of the MCT protein. Methods for diagnosis and / or treatment of a disease, such as a disorder of thyroid metabolism, non-thyroidal illness, obesity or cardiovascular illness, are also provided, as well as bioassays for identifying or detecting a candidate drug capable of binding to, or influencing at least part of, the MCT protein.

A topical preparation for treating first and second degree burns includes TriAc. The topical preparation preferably includes less than 10 mg of TriAc per 100 ml of pharmaceutical excipient base. In another embodiment, a topical preparation includes TriAc for decreasing cellulite. In this embodiment, the topical preparation is preferably applied only before exercise. In a preferred embodiment, the preparation is applied only intermittently, preferably no more than three times a week, or in amounts sufficient to not downregulate receptor number and become inefficacious.